TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: Preliminary outcomes in cohort A

Abstract

Background: In GTN patients resistant to chemotherapy, standard treatments include historic single agent or polychemotherapy regimens, known to be effective (65%-95% successful hCG normalization) and toxic. PD-L1 is constitutively expressed in all GTN subtypes (Bolze et al. Int J Gynecol Cancer 2017). The objective of TROPHIMMUN trial is to assess the efficacy of the anti-PD-L1 monoclonal antibody avelumab (Pfizer & Merck Serono) in patients with chemoresistant GTN.